Back to top
more

Alcon (ALC)

(Real Time Quote from BATS)

$94.30 USD

94.30
291,212

-0.17 (-0.18%)

Updated Sep 5, 2024 01:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

Protect Your Portfolio From Volatility With 3 Low-Beta Picks

by Indrajit Bandyopadhyay

At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.

Here's Why Investors Should Retain Acadia Healthcare (ACHC)

by Zacks Equity Research

Acadia Healthcare (ACHC) is well-poised for growth on the solid demand for behavioral healthcare services, the continuous pursuit of expansion initiatives and growing cash reserves.

Is Alcon (ALC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and Molina (MOH) have performed compared to their sector so far this year.

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC) on the impressive performance of its portfolio.

Alcon (ALC) Gains From Innovation & International Expansion

by Zacks Equity Research

Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.

Sheraz Mian headshot

Top Stock Reports for Visa, Chubb & HCA Healthcare

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Chubb Limited (CB) and HCA Healthcare, Inc. (HCA).

Waters (WAT) Walk-Up Solutions Boost Bioprocess Development

by Zacks Equity Research

Waters (WAT) launches new bioprocess walk-up solutions, automating sample prep and analysis from any bioreactor.

Here's Why You Should Retain Centene (CNC) in Your Portfolio

by Zacks Equity Research

Strong growth in membership, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.

Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity

by Zacks Equity Research

Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.

Community Health (CYH), Mindoula to Offer Mental Health Care

by Zacks Equity Research

Community Health (CYH) collaborates with Mindoula to enhance the availability of behavioral health resources to its affiliated provider network, who can now treat patients better.

Are Options Traders Betting on a Big Move in Alcon (ALC) Stock?

by Zacks Equity Research

Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.

Are Medical Stocks Lagging Adagene (ADAG) This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

3 MedTech Stocks to Bet on Potential Pause of Rate Hike by Fed

by Indrajit Bandyopadhyay

Interest rates impact the healthcare industry and medical device companies in various ways. Here we discuss three companies HCA, ALC and SEM that are likely to gain potential pause in rate hikes.

Centene (CNC) Divests Circle Health Group, Optimizes Portfolio

by Zacks Equity Research

Centene (CNC) announces the sale of Circle Health Group to PureHealth in a bid to dispose of non-core assets and grow its core Managed Care business.

Cigna (CI) Eases Care Delivery With Prior Authorization Removal

by Zacks Equity Research

Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.

Has Alcon (ALC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.

3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase

by Zacks Equity Research

Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.

Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Shaun Pruitt headshot

Time to Buy These Medical Stocks as Earnings Approach

by Shaun Pruitt

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

Alcon (ALC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.

Here's Why You Should Invest in Alcon (ALC) Stock Now

by Zacks Equity Research

Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.

Zacks Industry Outlook Highlights Alcon, Hologic and Penumbra

by Zacks Equity Research

Alcon, Hologic and Penumbra have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on rising demand for digital health. ALC, HOLX and PEN are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.

Select Medical (SEM) Expects Q2 Adjusted EBITDA to Jump 21% Y/Y

by Zacks Equity Research

Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.